A randomised controlled trial to investigate the effectiveness of the healthy sexual functioning module and selective serotonin reuptake inhibitor medication to treat deviant sexual arousal as part of the HM prison sex offender treatment programme

Department of Health (UK)0 个研究点目标入组 480 人开始时间: 2006年6月7日最近更新: 2023年2月6日

适应症

试验速览

暂无简介。

•Consent to treatment in HSF module of HM prison sex offender treatment programme with written informed consent.
•In addition, for SSRI sub-study, any one of the following:
•1. Sexual preoccupation (either from clinical assessment or based on the multiphasic sex inventory [MSI] obsession scale)
•2. A compulsive aspect to their offending (based on clinical judgement)
•3. Mood state being an important contributor to their offending (based on clinical judgement)
•4. Impulsivity (based on clinical judgement or impulsivity score)

•HSF evaluation: urgent treatment need as assessed by the treatment manager
•SSRI sub-study only:
•1. Presence of psychotic disorder or major mood disorder, epilepsy, uncontrolled seizure disorders, diabetes, major cardiac problems or severe renal failure.
•2. Concomitant treatment with psychoactive medication which may interact with the effects of the SSRI e.g. neuroleptic or antidepressant medication
•3. Concomitant treatment with an anti-androgen
•4. Concomitant treatment with an anti-coagulant
•5. Current treatment, or treatment within the last 4 weeks with SSRI
•6. Previous adverse reaction to an SSRI

发起方

Department of Health (UK)